secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2026-03-23T23:59:59+00:00
Accession:  0001104659-26-033079
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott completes $105/share cash acquisition of Exact Sciences, expanding cancer diagnostics
--------------------------------------------------------------------------------

- Abbott completed acquisition of Exact Sciences for $105/share cash; Exact becomes wholly owned subsidiary.
- Exact Sciences last trading day was March 20, 2026; shares converted to $105 cash.
- Deal adds Cologuard, Oncotype DX, Oncodetect, Cancerguard cancer screening diagnostics.
- Abbott becomes leader in $60B U.S. cancer screening and precision oncology diagnostics market.
- Acquisition adds growth vertical to Abbott's high-single-digit growth expectations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000110465926033079/0001104659-26-033079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000110465926033079/tm268709d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-033079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer